Certuity LLC Sells 108 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Certuity LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,414 shares of the biopharmaceutical company’s stock after selling 108 shares during the quarter. Certuity LLC’s holdings in Regeneron Pharmaceuticals were worth $1,007,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mizuho Securities USA LLC grew its stake in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after acquiring an additional 51,162 shares during the period. Principal Financial Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 3,231 shares in the last quarter. Golden State Equity Partners lifted its holdings in Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 1,272 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $1,334,000. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. TD Cowen dropped their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Barclays lowered their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN opened at $665.46 on Wednesday. The stock’s 50 day simple moving average is $714.37 and its 200 day simple moving average is $906.38. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm has a market cap of $73.13 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $11.86 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.